Prosthetics and Orthotics Market: as Embla Medical acquires majority ownership of a European fabrication specialist to position itself as a full-range provider spanning device manufacturing through custom fitting production, the largest global prosthetics companies are converging on vertical integration as the defining strategy of this decade, extending their reach beyond component design into the fabrication and clinical service layers that ultimately determine how a device actually reaches the patient who needs it.

The global prosthetics and orthotics market size was USD 10.82 Billion in 2025 and is expected to register a revenue CAGR of 6.2% during the forecast period. Market revenue growth is driven by factors such as microprocessor-controlled and bionic prosthetic technology adoption expanding functional independence for amputees, vertical integration by the largest global manufacturers spanning device fabrication through clinical service delivery, and reimbursement policy expansion improving patient access to advanced prosthetic technology. The first driving factor is microprocessor-controlled and bionic prosthetic technology adoption, which expands functional independence and mobility for amputee users beyond what conventional mechanical prosthetic components can provide. Lower limb prosthetics account for a substantial share of total 2025 market revenue, reflecting this category's centrality to the majority of amputee rehabilitation cases. The second driving factor is vertical integration by the largest global manufacturers, as companies acquire fabrication, clinical service, and neuro orthotics capability to build comprehensive, full-range prosthetics and orthotics businesses. The third driving factor is reimbursement policy expansion, as public and private payers broaden coverage criteria for advanced prosthetic technology previously restricted to the highest-mobility patient classifications. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single manufacturer's acquisition of a specialised fabrication or clinical service business converts a conventional component design and manufacturing operation into a broader, full-range business spanning device design through custom fitting and patient-facing clinical service, which lets that manufacturer capture revenue across the entire prosthetic or orthotic patient journey rather than the device sale alone. Because a prosthetic or orthotic device's ultimate clinical value depends significantly on custom fabrication and fitting quality delivered close to the patient, a manufacturer that also controls fabrication and clinical service capability captures a much larger share of the total patient care revenue stream than a company selling only components to independent fabrication and fitting providers. As a result, demand and revenue share are concentrating around manufacturers pursuing vertical integration across design, fabrication, and clinical service, and the forecast tilts toward these full-range providers rather than companies competing purely as component manufacturers. For instance, in 2025, Embla Medical acquired a majority share in Streifeneder ortho.production, positioning the company as a full-range provider spanning device manufacturing through custom fabrication production, strengthening its presence in key European markets and expanding its vertically integrated business model. These are some of the key factors driving revenue growth of the market.

Because microprocessor-controlled and bionic prosthetic components carry substantially higher unit cost than conventional mechanical alternatives, adoption of this technology remains concentrated in markets with well-developed public or private reimbursement infrastructure, which limits broader global accessibility even as the underlying technology continues to improve.

The shortage of certified prosthetists and orthotists constraining fitting and clinical service capacity is a second constraint, since even a well-reimbursed, technologically advanced device requires skilled custom fitting to deliver its intended clinical benefit, and workforce shortages in this specialised clinical field can delay patient access regardless of device availability or reimbursement status.

Emerging market affordability and access gaps are a third constraint, since only 30 to 40% of new amputees globally are fitted with prosthetic solutions at all, reflecting substantial unmet need concentrated in markets with less developed prosthetic manufacturing, fitting, and reimbursement infrastructure.

These factors substantially limit prosthetics and orthotics market growth over the forecast period.

The clearest driver of demand is microprocessor-controlled and bionic prosthetic technology adoption, which expands functional independence and mobility for amputee users beyond what conventional mechanical prosthetic components can provide. A conventional mechanical prosthetic knee or foot requires the user to compensate actively for the device's lack of adaptive response to varying terrain and gait patterns, so microprocessor-controlled and bionic components that adjust automatically to these variables directly reduce user fatigue and fall risk while expanding the range of activities a user can confidently pursue. Lower limb prosthetics account for a substantial share of total 2025 market revenue, and Embla Medical launched the NAVii bionic knee under its Össur brand alongside the Icon microprocessor knee under its College Park brand, two new high-end bionic knee solutions launched for high-active and versatile amputee applications. The effect on the market is that bionic and microprocessor-controlled technology continues capturing share from conventional mechanical prosthetic components across an expanding range of user mobility classifications. These are some of the key factors driving revenue growth of the market.

The second driver is vertical integration by the largest global manufacturers, as companies acquire fabrication, clinical service, and neuro orthotics capability to build comprehensive, full-range prosthetics and orthotics businesses spanning the entire patient care continuum. A prosthetic or orthotic device's ultimate clinical value depends significantly on custom fabrication and fitting quality delivered close to the patient, so a manufacturer that also controls fabrication and clinical service capability captures a much larger share of the total patient care revenue stream than a company selling only components to independent fabrication and fitting providers. In 2025, Embla Medical acquired a majority share in Streifeneder ortho.production, positioning the company as a full-range provider spanning device manufacturing through custom fabrication production and strengthening its presence in key European markets, building on the company's 2024 acquisition of Fior and Gentz to enter the neuro orthotics category. The effect on the market is that the largest global manufacturers increasingly compete on the breadth of their integrated design, fabrication, and clinical service capability, not device technology alone. These are some of the key factors driving revenue growth of the market.

Embla Medical's 2025 acquisition of a majority share in Streifeneder ortho.production builds directly on its 2024 Fior and Gentz neuro orthotics acquisition. The largest global prosthetics companies are converging on vertical integration, spanning device fabrication through clinical service delivery, as this decade's defining competitive strategy.

The third driver is reimbursement policy expansion, as public and private payers broaden coverage criteria for advanced prosthetic technology previously restricted to the highest-mobility patient classifications. A payer's functional mobility classification system historically restricted access to bionic and microprocessor-controlled prosthetic components to only the highest-mobility amputee classifications, so an expanded coverage policy that extends access to a broader mobility classification directly increases the addressable patient population for advanced prosthetic technology. CMS finalised the US Medicare K2 expanded access policy, granting active K2 ambulatory amputees access to bionic prosthetic knees and feet previously restricted to K3 and K4 mobility classifications, representing the most significant US prosthetic reimbursement expansion in years. The effect on the market is that the addressable patient population for advanced bionic and microprocessor-controlled prosthetic technology has expanded meaningfully within the US market specifically, with comparable policy expansion under active consideration in other major markets. These are some of the key factors driving revenue growth of the market.

However, the prosthetics and orthotics market faces severe adoption constraints from premium cost for microprocessor-controlled and bionic prosthetic technology limiting adoption in markets with less developed reimbursement infrastructure, and the shortage of certified prosthetists and orthotists constraining fitting and clinical service capacity even where device technology and reimbursement are otherwise available.

Because microprocessor-controlled and bionic prosthetic components, including Embla Medical's newly launched NAVii and Icon knee platforms, carry substantially higher unit cost than conventional mechanical alternatives, adoption of this technology remains concentrated in markets with well-developed public or private reimbursement infrastructure, which limits broader global accessibility even as the underlying technology continues to improve.

The shortage of certified prosthetists and orthotists constraining fitting and clinical service capacity compounds this, since even a well-reimbursed, technologically advanced device requires skilled custom fitting to deliver its intended clinical benefit, and workforce shortages in this specialised clinical field can delay patient access regardless of device availability or reimbursement status, a gap vertically integrated companies like Embla Medical are specifically trying to address through fabrication and clinical service acquisition.

Emerging market affordability and access gaps are the third constraint, since only 30 to 40% of new amputees globally are fitted with prosthetic solutions at all, reflecting substantial unmet need concentrated in markets with less developed prosthetic manufacturing, fitting, and reimbursement infrastructure.

These factors substantially limit prosthetics and orthotics market growth over the forecast period.

Based on product, the global prosthetics and orthotics market is segmented into lower limb prosthetics, upper limb prosthetics, orthotics, and neuro orthotics and gait rehabilitation devices. Lower limb prosthetics hold the largest revenue share, because lower limb amputation represents the most common amputation category globally and commands higher per-unit device pricing than most orthotic bracing products, which suits a market where the highest-volume, highest-value amputee rehabilitation category commands the largest revenue category. Orthotics remain a substantial, closely established second category given their use across musculoskeletal and neurological rehabilitation broadly. Neuro orthotics and gait rehabilitation devices are expected to register the fastest revenue growth rate in the global prosthetics and orthotics market over the forecast period, driven by Embla Medical's Fior and Gentz acquisition and continued neurological gait rehabilitation expansion.

Based on technology, the global prosthetics and orthotics market is segmented into conventional mechanical, microprocessor-controlled, and bionic or myoelectric and AI-assisted technology tiers. Microprocessor-controlled technology holds a significant revenue share, because it commands substantially higher pricing than conventional mechanical components while addressing a broad range of amputee mobility classifications, which ties directly back to the reimbursement policy expansion described in the market's primary demand driver. Bionic and myoelectric technology is expected to register the fastest revenue growth rate in the global prosthetics and orthotics market over the forecast period, driven by Embla Medical's NAVii and Icon bionic knee launches and comparable next-generation platforms.

Amputee rehabilitation and prosthetic fitting application is expected to account for the largest revenue share in the global prosthetics and orthotics market during the forecast period

Based on application, the global prosthetics and orthotics market is segmented into amputee rehabilitation and prosthetic fitting, neurological and post-stroke rehabilitation, and musculoskeletal and sports injury bracing. Amputee rehabilitation and prosthetic fitting holds the largest revenue share, reflecting the concentration of prosthetic device revenue within this core clinical application. Neurological and post-stroke rehabilitation is expected to register the fastest revenue growth rate in the global prosthetics and orthotics market over the forecast period, driven by expanding neuro orthotics technology adoption following acquisitions like Embla Medical's Fior and Gentz deal.

Based on regional analysis, the prosthetics and orthotics market in North America accounted for largest revenue share in 2025. The United States leads because CMS's K2 expanded access policy and the concentration of Hanger's clinic network create the deepest and most reimbursement-supported prosthetics demand globally, and because Ottobock, Embla Medical, and Hanger all maintain significant commercial presence in the US market. Hanger's position as the largest US O&P clinic network, reinforced by its February 2024 acquisition of Fillauer, specifically anchors the depth of domestic clinical service capacity. The concentration of CMS reimbursement policy development in the country also means new coverage expansion typically establishes in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, Iceland, and the United Kingdom represent significant national markets within Europe, anchored by Ottobock's German headquarters and Embla Medical's Iceland-based parent structure. Embla Medical's Streifeneder ortho.production acquisition specifically strengthens the company's fabrication presence across key European markets. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and India represent two of the largest national markets within the region, driven by expanding disability support infrastructure and rising amputee rehabilitation access. The region's rapidly scaling healthcare infrastructure leaves considerably more room for growth than in the already prosthetics-mature North American and European markets, given the substantial existing unmet global need for prosthetic fitting.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding disability support infrastructure driving early prosthetics and orthotics demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the carbon fibre and specialised electronic components that Latin American prosthetics manufacturers depend on, an effect expected to run through 2026 and slow prosthetics and orthotics adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding disability support programmes and the UAE's regional distribution hubs represent the primary investment centres for prosthetics and orthotics adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the clinical fitting and reimbursement infrastructure needed to support advanced prosthetic technology at scale.